Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 16/20 | 0.52 |
| ▸ | CDK2 | P24941 | 7/20 | 0.52 |
| ▸ | AURKA | O14965 | 5/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.52 |
| ▸ | PRKCG | P05129 | 5/20 | 0.52 |
| ▸ | PRKCB | P05771 | 5/20 | 0.52 |
| ▸ | PRKCA | P17252 | 5/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.52 |
| ▸ | PRKCH | P24723 | 5/20 | 0.52 |
| ▸ | PRKCI | P41743 | 5/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.52 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.45 |
| ▸ | CCNK | O75909 | 2/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054799 | 0.90 | CHEK1 (0.58) | CHEK1CDK2AURKAPRKD3PRKCG | |
| SCHEMBL4283539 | 0.89 | CHEK1 (0.52) | CHEK1CDK2AURKAPRKD3PRKCG | |
| SCHEMBL4297257 | 0.89 | CHEK1 (0.66) | CHEK1CDK2AURKAPRKD3PRKCG | |
| SCHEMBL4286318 | 0.83 | CHEK1 (0.51) | CHEK1CDK2AURKAPRKD3PRKCG | |
| SCHEMBL4286338 | 0.83 | CHEK1 (0.65) | CHEK1CDK2AURKAPRKD3PRKCG | |
| SCHEMBL14796277 | 0.79 | CHEK1 (0.81) | CHEK1CDK2AURKAPRKD3PRKCG | |
| SCHEMBL4282498 | 0.78 | CHEK1 (0.52) | CHEK1CDK2AURKAPRKD3PRKCG | |
| SCHEMBL4291461 | 0.78 | CHEK1 (0.62) | CHEK1CDK2AURKAPRKD3PRKCG | |
| SCHEMBL4286313 | 0.77 | CHEK1 (0.64) | CHEK1JAK1 | |
| SCHEMBL4285975 | 0.77 | CHEK1 (0.64) | CHEK1CDK2AURKAPRKD3PRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CHEK1 3620/4885CDK2 2064/4885AURKA 1205/4885 |
| US-20090181979-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CHEK1 3620/4885CDK2 2064/4885AURKA 1205/4885 |
| US-20050209247-A1 | Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors | KDR, FLT4, FLT1 | CHEK1 1873/4885CDK2 171/4885AURKA 117/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CHEK1 3620/4885CDK2 2064/4885AURKA 1205/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | CHEK1 3620/4885CDK2 2064/4885AURKA 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.